Role of stem cell therapy in diabetic nephropathy in rats: biochemical, histological and immunohistochemical study

Ahmed Y. Sedeak¹, Hanan D. Yassa¹, Azza S. Moawad¹, Abdalwakel A. Mohammed², Gaber H. Abdelfatah¹

¹ Anatomy and Embryology Department, Faculty of Medicine, Beni-Suef University, Egypt
² Anatomy and Embryology Department, Faculty of Medicine, Cairo University, Egypt
³ Histology Department, Faculty of Medicine, Beni-Suef University, Egypt

SUMMARY

Diabetes mellitus is one of the main causes of death due to the complications that involve many organs such as heart, kidney, retina and others. Mesenchymal stem cells (MSCs) have been demonstrated to be effective in treatment of diabetes. This paper aims to evaluate the effect of stem cells in the treatment of diabetic nephropathy, clarifying their role in oxidative stress and inflammation. 30 adult male albino rats were equally divided into 3 groups. Control group (group I) received 1ml saline by intra-peritoneal (IP) injection. Streptozotocin-treated group (group II) received Streptozotocin (STZ) (60 mg/kg BW, I.P.) for induction of diabetes, then were sacrificed after 4 weeks. Steptozotocin + Stem cell-treated group (group III) received STZ, were left for 4 weeks, and then they were injected once intravenously with 1 million units of MSC and sacrificed after 4 weeks. Blood glucose, serum urea and creatinine were checked. The kidney sections were examined Histologically with H&E and PAS Stain and immunohistochemically for endothelial Nitric Oxide Synthase (eNOS). A morphometric study and statistical analysis were performed. DM led to increased levels of glucose, urea and creatine. Also, DM caused inflammation, degeneration and decreased eNOS immunoexpression of the kidney. The administration of MSCs improved the levels of glucose, urea and creatinine. Also, MSCs decreased the pathological changes and increased eNOS immunoexpression in the kidney. MSCs have effective therapeutic role in treating diabetic nephropathy.

Key words: Diabetes – Nephropathy – Mesenchymal stem cell – eNOS – Oxidative stress

INTRODUCTION

Diabetes mellitus (DM) is one of the most prevalent non-communicable metabolic diseases. Recent years have showed a sudden increase of diabetes all over the world. The International Diabetes Federation (IDF) reported that the number of diabetic populations will increase from 415 million in 2015 to 642 million by 2040 (Peng et al., 2018).

Submitted: November 10, 2020. Accepted: March 11, 2021
The effectiveness of MSCs was demonstrated in the treatment of diabetes and its complications, including microvascular complications such as retinopathy (Yang et al., 2010) and nephropathy (Fang et al., 2012), and macrovascular complications such as cardiomyopathy (Abdel Aziz et al., 2008).

Diabetic nephropathy is a major microvascular complication in patients with diabetes, and remains the leading cause of chronic kidney disease, accounting for approximately a half of all end-stage renal disease worldwide (Kanwar et al., 2011).

Streptozotocin (STZ) is one of antibiotics that obtained from Streptomyces achromogenes. It has been widely used for inducing experimental diabetes mellitus in a variety of animals, as it causes degeneration of pancreatic β cells causing insufficient insulin secretion (Mousa et al., 2016).

Stem cell treatment is a recent type of intervention strategy that is introduced into the damaged tissues in order to treat diseases or injuries. Many medical researchers believe that stem cell treatment has the potential to change the prospect of human diseases and alleviate suffering. The stem cells are able to proliferate and give rise to subsequent generations with variable degrees of differentiation capacities. This ability offers significant potential for the generation of tissues that can replace diseased and damaged tissues in the body (Mousa et al., 2016).

Mesenchymal stem cells (MSCs) secrete numerous factors, such as nitric oxide and prostaglandin E2, which enhance antioxidant defenses, inhibit oxidation factors and reduce necrosis of the cells (Pulavendran et al., 2010; Berrardis et al., 2015). Furthermore, immune modulation of MSCs inhibits inflammatory cell proliferation, thereby exerting anti-inflammatory effects (Volarevic et al., 2014).

The goal of this study was to reveal the changes induced by diabetes on the kidney clarifying the possible therapeutic effects of MSCs through histological, immunohistochemical and biochemical studies.

MATERIALS AND METHODS

The study was carried out at the Animal House of the Faculty of Medicine, Cairo University, according to the guide lines used for the care and the use of laboratory animals (code of ethical approval is 018-61).

Experimental animals

The study was performed on 30 adult male albino rats of an average weight 150-180 g. The rats were acclimatized in the laboratory for a period of two weeks before performing the experiment. They were manipulated in cages made of metal under standard laboratory and pathogen-free environmental conditions. The rats were nourished using standard levels of the rodent water and food. These rats were equally divided into 3 groups:

Control group (group I): this group received 1ml saline by intra-peritoneal (IP) injection.

Streptozotocin-treated group (group II): this group received Streptozotocin (STZ) (60 mg/kg body weight (BW), I.P .) for induction of diabetes; then they were sacrificed after 4 weeks (Srinivasan et al., 2005).

Steptozotocin+ Stem cell-treated group (group III): this group received STZ for induction of diabetes and left for 4 weeks, then these rats were intravenously injected with 1 million units of bone marrow-derived mesenchymal stem cells (BM-derived MSCs) only for one time. After 4 weeks of being treated with stem cells, these rats were sacrificed (Ngoc et al., 2011).

Chemicals

Streptozotocin (STZ) was obtained from Sigma Company (St. Louis Mo, USA) in the form of powder solvent. Each vial of Streptozotocin powder contain 1 gram of Streptozotocin-active ingredient with the chemical name, N(MethylNitrosocarbamoyl)-α-D-glucosamine Streptozotocin.

Induction of DM: STZ (60 mg/kg BW) was dissolved in 0.1M sodium citrate buffer in the Biochemistry department, Faculty of Medicine, Cairo University. Preparation of the solution was done at pH 4.5 and then injected intravenously within 15 min. The aim of this procedure is to induce T1DM (Cesaretti et al., 2010).

Diagnosis of Diabetes: Polydipsia and Polyphagia were observed in adult rats within three days of
injection of streptozotocin and this suggested DM due to destruction of β-cells of Langerhans islet cells (Bluestone et al., 2010). Diagnosis of diabetes was approved by elevation of blood glucose level (Ikebukuro et al., 2002). Rats with blood glucose levels more than 200 mg/dL were considered diabetic (Cesaretti et al., 2010).

**Treatment of DM:** Preparation of Labeled bone marrow-derived mesenchymal stem cells was done in the stem cell unit, Biochemistry department, Faculty of Medicine, Cairo University. These stem cells were given by single I.V. injection in a dose of 1ml of about \((1\times10^6 \text{ cells/rat})\) 4 weeks after confirmation of diabetes (Kajiyama et al., 2010). The treatment was allowed only to the third group suspended in 1 ml normal saline (Carr et al., 2008).

**Isolation and culture of bone marrow-derived mesenchymal stem cells (BM-derived MSCs) (Jiang et al., 2010):**

5-bromo-2′-deoxy-uridine (BrdU) labeled MSCs were prepared at Medical Biochemistry Department, Faculty of medicine, Cairo University. Isolated and cultivation of BM-derived MSCs were carried out for 4 weeks. Adult rats were euthanized and bilateral femora and tibias were removed under sterile conditions and placed in Dulbecco’s modified eagle medium (DMEM; Gibco/BRL). Flushing out of MSCs was performed with DMEM using a syringe fitted with a 23-gauge needle. This was followed by gently pipetting bone marrow from each bone many times to separate cells. Then the cells were washed two times using DMEM, centrifuged 2250 rpm for 15min, and cultured in DMEM supplemented with 10% fetal bovine serum (GibcoBRL), 100 U/ml penicillin G and 100mg/ml streptomycin (GibcoBRL) at 2.5x10⁷/cm². The cells were incubated at 37 °C in humidified 95% air and 5% CO2.

3 days later, elimination of non-adherent cells was done. Addition of fresh complete culture medium DMEM was done and then replaced every 3 or 4 days. When the cells become 80-90% confluent over 14 days, they were harvested with 0.25% trypsin and one mmol EDTA (GibcoBRL) for 3 min at 37° C, replanted in six-well disk at 1.5x10⁷/cm² and again grown to near confluence. Dilution of cells was obtained by adding water 1:2 per passage to expand the culture.

Fluorescence phase-contrast microscope (Axio-cam MR3, Carl Zeiss, Germany) was used to observe the rats MSCs every 2 or 3 days.

**Biochemical study**

At the end of the experiment of each group, collection of blood samples were carried out using fine heparinized capillary tube. The blood samples were delivered into centrifuge tubes and the plasma was collected and used for the determination of glucose, urea and creatinine.

Anaesthesia of the rats was performed using mild ether inhalation then subsequent sacrifice of these rats was done by cervical dislocation to avoid chemical injury (Liu et al., 2013). The rats’ kidneys were excised immediately and carefully.

**Histological study**

The kidneys were dissected, fixed in 10% formalin overnight, processed for paraffin blocks and sectioned at 5 µm thickness. Sections of paraffin were used in:

1. Hematoxylin & Eosin stain (Kiernan, 2015)
2. PAS (Bancroft and Gamble, 2008)
3. Immunohistochemical study using endothelial nitric oxide synthase (eNOS) (Takahashi and Harris, 2014): Primary antibody: endothelial Nitric Oxide Synthase (eNOS) antibody, a mouse monoclonal [M221] antibody (IgG1) (Abcam Medical, Cambridge, USA, catalogue number ab76198) to eNOS and it consists of recombinant part of mouse eNOS protein which contained residues of amino acid in the C-terminal region. It is liquid and stored at -20°C in 0.05% sodium azide. Heart section was used as a standard positive control. One of the kidney sections was used as a negative control by avoiding application of the primary antibody.

**Fluorescent microscopic examination**

Kidney Sections of STZ+stem cell group were submitted to fluorescent microscopy.
examination to clarify fluorescent labeled mesenchymal stem cells (Fig. 1). It was done by detecting the Bromodeoxyuridine (BrdU) - positive cells in the sections. The sections were immunostained using mouse anti-BrdU (1:100, Neomarkers), and goat anti-mouse Ig GFITC (1:100, Kpl).

Morphometric study

Using a Leica Quin 500 (Leica Ltd, Cambridge, UK) computerized image analysis system, the morphometric studies were done for the intensity of the eNOS immunoexpression in the kidney sections.

Statistical analysis (Emsley et al, 2010):

Analysis of Statistics was done using SPSS software, version 16. All data will be expressed as mean ± SD. One way analysis of variance (ANOVA) test will be used for comparison between rat groups. The results of Statistics were considered significant when the p-values were < 0.05.

RESULTS

No deaths were detected in rats.

Biochemical results

The mean values of glucose, urea and creatinine levels of STZ group were significantly increased as compared with the control group (P-value < 0.05) (Table 1).

The mean value of glucose, urea and creatinine levels of STZ+ Stem cell-treated group were significantly decreased as compared with the STZ treated group (P-value < 0.05) (Table 1).

HISTOLOGICAL RESULTS

H and E stain results (Figs. 5, 6)

In the control group, H&E-stained sections of the kidneys revealed normal renal architecture in the form of Malpighian corpuscles formed of a glomerulus surrounded by Bowman's capsule, proximal and distal convoluted tubules (Fig. 2).

Fig. 1.- Fluorescent microscopic kidney section of the STZ+MSCs group shows fluorescent illumination of fluorescent-labeled mesenchymal stem cells. Scale bar = 50 µm.
In the STZ-treated group, renal sections showed hypertrophic glomeruli and obliteration of the capsular spaces (Fig. 3). Renal sections also revealed cytoplasmic vacuolization of the tubular cells (Figs. 3, 4). Multiple tubules with intraluminal acidophilic masses and congested blood vessels were demonstrated (Fig. 4). There was massive mononuclear cellular infiltration (Fig. 3).

The kidneys of STZ+ Stem cell-treated group revealed normal Malpighian corpuscles formed of a glomerulus surrounded by Bowman’s capsule and normal tubules whereas some tubules were dilated (Fig. 5).

**PAS stain results (Fig. 6)**

Using PAS stain, the control kidneys displayed the parietal layer of the Bowman’s capsule, the basement membrane of renal tubule and the brush border of the proximal convoluted tubule. However, in STZ-treated group, there was thickening of parietal layer of the Bowman’s capsule, as well as basement membrane of the

---

**Table 1.** Comparison between all groups (control, STZ treated and STZ+ Stem cell-treated G) regarding blood glucose level, urea level, creatinine level and intensity of eNOS immunoexpression in the kidney sections (mean ± standard deviation).

<table>
<thead>
<tr>
<th>Groups</th>
<th>Blood glucose level</th>
<th>Urea level</th>
<th>Creatinine level</th>
<th>Intensity of eNOS immunoexpression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>92.62 ± 6.49</td>
<td>37.9 ± 3.84</td>
<td>0.21 ± 0.02</td>
<td>33180870 ± 2446319</td>
</tr>
<tr>
<td>STZ treated</td>
<td>284.84 ± 19.18*</td>
<td>72.1 ± 9.06*</td>
<td>0.93 ± 0.25*</td>
<td>7887416 ± 1071690*</td>
</tr>
<tr>
<td>STZ+ Stem cell-treated</td>
<td>142.93 ± 13.10</td>
<td>47.3 ± 5.25</td>
<td>0.32 ± 0.06</td>
<td>28624580 ± 2121946</td>
</tr>
</tbody>
</table>

*Significant (P< 0.05) compared with other groups.
Role of stem cell therapy in diabetic nephropathy in rats: biochemical, histological and immunohistochemical study

Fig. 3.- Renal cortical sections of the STZ treated group. (A) hypertrophic glomeruli and obliteration of the capsular spaces (thick arrow) and cytoplasmic vacuolation of the renal tubules (thin arrows). (B) massive mononuclear cellular infiltration (I) and cytoplasmic vacuolizations of the tubular cells (arrows). Scale bars = 100 µm.

Fig. 4.- Renal cortical section of the STZ treated group. (A) cytoplasmic vacuolization of the tubular cells (arrows). (B) multiple tubules with intraluminal acidophilic masses (thick arrows) and congested blood vessels (C). Scale bars = 50 µm.
renal tubules. Partial loss of brush border of some proximal convoluted tubules was detected. While, in STZ+ Stem cell-treated group, there was thin parietal layer of the Bowman's capsule and basement membrane of renal tubule. Brush border of proximal convoluted tubules could be seen mostly intact.

**Immunohistochemical results (Fig. 7)**

Immunohistochemical staining of the kidneys for (eNOS) demonstrated positive eNOS immunoexpression in the glomerular vascular endothelial cells. However, in STZ-treated group, immunohistochemical staining of the kidneys for (eNOS) demonstrated less intensity of the eNOS immunoexpression in the glomerular vascular endothelium in comparison with the control group. While the STZ+ Stem cell-treated group showed increased intensity of the eNOS immunoexpression.

**Morphometric results**

The intensity of eNOS immunoexpression in STZ group was significantly decreased as compared with the control group (P-value < 0.05) (Table 1).

The intensity of eNOS immunoexpression in STZ+stem cell group showed a significant increase as compared with the STZ treated group (P-value < 0.05) (Table 1).

**DISCUSSION**

In the present work, the diabetic rats developed diabetic nephropathy detected biochemically and histologically. Regarding the biochemical results of the kidney, renal dysfunction is detected by elevated serum urea and creatinine. Similar to the current work, Abdel Aziz et al., (2014) reported that one of the most sensitive and dramatic indicators of kidney injury is the increase of creatinine and urea level in the circulation following STZ administration.
Fig. 6.- PAS-stained renal cortical sections of control (A), STZ treated (B) and STZ+ stem cell treated (C) groups. (B) shows in comparison with (A) thickening of parietal layer of Bowman’s capsule (thick arrow) as well as basement membrane of renal tubules (thin arrows). Partial loss of brush border of some proximal convoluted tubules could be seen (arrowhead). (C) shows thin parietal layer of Bowman’s capsule and basement membrane of renal tubule. Brush border of proximal convoluted tubules could be detected mostly intact. Scale bars = 50 µm.

Fig. 7.- eNOS immunostained renal sections of control (A), STZ treated (B) and STZ+ stem cell treated (C). (A) shows brown coloration (positive eNOS immunoexpression) in the glomerular vascular endothelium (arrows). (B) shows decreased intensity of the eNOS immunoexpression while (C) shows an increase of the intensity. Scale bars = 20 µm.
The results of the current study are in accordance with Kaur et al. (2015), who reported that the single dose administration of STZ in rats has been shown to produce diabetic nephropathy (DN) after 6 weeks, and stated that the serum creatinine levels were noted to be increased markedly in STZ treated rats on day 42nd as compared to the control group. Also, Lu et al. (2007) and Shaker et al. (2015) reported that urea and creatinine levels were increased in DN rat model induced by streptozotocin.

Multiple mechanisms contribute to the development and outcomes of diabetic nephropathy such as an interaction between hyperglycemia-induced metabolic and hemodynamic changes and genetic predisposition, which sets the stage for kidney injury (Li et al., 2018).

Another theory was detected by Mousa et al. (2016) who postulated that the elevation in serum urea and creatinine of STZ diabetic animals could be attributed to the functional and/or morphological changes in the kidneys.

However, Sriram and Subramanian (2011) showed that the increased concentrations of urea and creatinine in blood was due to diabetic oxidative stress and impaired balance of nitrogen coupled with lowered protein synthesis.

The current work detected that administration of BM-MSCs in diabetic rats showed a significant improvement of kidney functions (urea and creatinine) as compared with diabetic group. This was agreed with Mousa et al. (2016) and Humphreys and Bonventre (2008), who detected an improvement of kidney functions after administration of stem cells, and this may be due to homing of MSCs to injured tissue causing its regeneration by its direct differentiation ability or by the paracrine factors released by MSCs. In agreement of the current study, the results of Semedo et al. (2009b) showed a significant improvement in kidney function in the diabetic group treated intravenously with a single dose of one million of MSCs per rat compared to DN group.

Abdel Aziz et al. (2014) reported that the administration of MSCs led to the amelioration of some functional parameters such as serum creatinine and urea levels. They referred this improvement in kidney function in MSCs-treated group to their paracrine action via different growth factors such as VEGF, TGF-β and TNF-α and antiapoptotic effects via Bax and Bcl2 genes.

Regarding the histological results, STZ injection caused structural alterations in the renal glomeruli which appeared hypertrophic with narrowed or obliterated Bowman’s space. These findings were similar to that of Shaker et al. (2015) and Zhou et al. (2009) who reported that kidney samples of diabetic nephropathy group showed exaggerated mesangial proliferation and thickened basement membrane.

Additionally, Patel et al. (2009) found that DM led to an elevation in oxidative damage inducing considerable injury in the glomeruli, disorders in matrix protein synthesis and increase in transforming growth factors-beta (TGF-β). However, Takahashi and Harris (2014) found that the diabetic nephropathic changes in the form of glomerular hypertrophy, mesangial expansion and nodular glomerulosclerosis were due to not only oxidative stress but also due to insulin resistance, hyperinsulinemia and hyperlipidemia.

In the present work, diabetic nephropathy was characterized by degenerated renal tubular cells with intraluminal acidophilic hyaline material that considered as hyaline casts. Moreover, there was a significant interstitial mononuclear cellular infiltration. This is in agreement with results reported by (Mundt and Shanahan, 2011).

These findings were analogous to the findings of Li et al. (2018), who indicated that renal morphologic abnormalities in DN rats including tubular degeneration, dilatation and protein cylinders at 8 weeks after STZ injection, confirming diabetic renal injury.

In the current study, light microscopic examination of the renal sections revealed the regaining of the normal appearance of most of the renal tissue including glomeruli, proximal and distal convoluted tubules in mesenchymal stem cell treated group after STZ administration. Comparable findings were observed by Asanuma et al. (2011) and Nagaishi et al. (2016) who revealed the therapeutic use of stem cells in diabetic nephropathy.
Many postulations were suggested to explain the mechanism of stem cells therapy in diabetic nephropathy. MSCs protects against diabetic nephropathy by restoring the biochemical alterations as well as inhibition of oxidative stress and pro-inflammatory gene expression levels suggesting a potential clinical use of MSCs to prevent the onset and progression of diabetic nephropathy according to Fang et al. (2012).

Another explanation is that the use of MSCs in type 1 diabetes (T1D) was based upon their immunoregulatory properties, which may help to rescue peripheral tolerance toward pancreatic β-cells by reshaping the immune response and blocking their damage by autoreactive T cells (Fiorina et al., 2011). A study made by Lee et al. (2006) mentioned that in diabetic mice, MSCs homed and promoted repair of pancreatic islets and renal glomeruli. The results raised the possibility that MSCs may be useful in enhancing insulin secretion and perhaps improving the renal lesions that develop in patients with diabetes mellitus.

Antioxidant effect of MSCs was suggested to be mediated through modulation of pathways associated with the activation of antioxidant pathways such as superoxide dismutase and glutathione peroxidase (Lanza et al., 2009). Transplantation of MSCs decreases inflammatory response of kidney in diabetic nephropathy. This leads to modulation of the inflammation via increasing IL10 cytokine and delays the progression of diabetic nephropathy. This beneficial effect is thought to be due to the anti-inflammatory factors such as IL10 produced by MSCs that are secreted in a paracrine fashion (Semedo et al., 2009b).

In the present work, PAS-stained kidney sections revealed marked thickening of parietal layer of Bowman’s capsule. The basement membranes of proximal and distal convoluted tubules were also thickened with loss of apical brush border of some proximal convoluted tubules. These results were in compliance with the finding of many researchers such as Wang et al. (2013), Nagaishi et al. (2016) and Li et al. (2018).

In STZ+ Stem cell-treated group, there were regaining the thin parietal layer of Bowman`s capsule, thin basement membrane of renal tubule and intact brush border of proximal convoluted tubules.

In the current work, the eNOS immunoexpression is detected in the glomerular endothelial cells of the kidneys of the control group. The glomerular endothelium of diabetic kidneys showed a significant decrease in the intensity of the eNOS immunoexpression compared to the endothelium of control kidneys. Also, there was a significant increase in the intensity of the eNOS immunoexpression in the glomerular endothelial cells of the kidneys in the STZ +stem cell treated group compared to the diabetic group. These findings were also detected by Aktug et al. (2012), who found that eNOS expression in the glomerular endothelial cells and the visceral and parietal layers of the capsule were stronger in the controls when compared to the diabetic group. According to their results, hyperglycemia inhibits eNOS leading to reduced nitric oxide production in endothelial cells. Inhibition of eNOS was correlated with glomerular cell loss due to apoptosis.

Animal models have explored the mechanisms by which the eNOS deficiency causes advanced DN and provided many new insights into the pathogenesis of DN (Takahashi and Harris, 2014). Hyperglycemia down regulates the expression and activity of eNOS and decreases the bioavailability of NO, which aggravates diabetic nephropathy according to (Casey et al., 2004).

Oxidative stress appears to be the most important pathogenic factor in underlying diabetic complications (Dave and Kalia, 2007). Higher levels of reactive oxygen species can induce the production of inflammatory cytokines in the kidney which enhances DN progression. One of the sources of inflammatory cytokines is bone marrow-derived cells that excessively infiltrate the kidneys fusing with the tubular epithelial cells causing parenchymal cells to produce cytotoxic tumor necrosis factor alpha (TNF-α) and caspase-3 which leads to degeneration and apoptosis in STZ-induced diabetes (Nagaishi et al., 2016).
CONCLUSION

MSCs transplantation can improve the levels of blood glucose and kidney functions (urea and creatinine) in STZ-induced diabetic rats. Also stem cells ameliorate the pathological changes of the kidneys in diabetic rats. Thus, stem cells provided a new line of treatment strategies in diabetes and diabetic nephropathy.

REFERENCES


